Ozempic maker Novo Nordisk downgraded to sell after 70% stock-price dive from peak

Deutsche Bank downgraded Novo Nordisk shares to sell on Thursday, marking the first sell rating from a major Wall Street analyst as the stock declined approximately 70 percent from its peak. The pharmaceutical company manufactures Ozempic, a diabetes and weight-loss medication. The downgrade came after an extended period during which major analysts had maintained hold or buy recommendations despite the stock's decline.

Next story